Zacks Research Analysts Increase Earnings Estimates for DYAI

Dyadic International Inc. (NASDAQ:DYAI) – Investment analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of Dyadic International in a research report issued to clients and investors on Wednesday, May 20th. Zacks Research analyst J. Vandermosten now expects that the biotechnology company will earn $0.13 per share for the year, up from their prior estimate of ($0.12). The consensus estimate for Dyadic International’s current full-year earnings is ($0.12) per share. Zacks Research also issued estimates for Dyadic International’s FY2027 earnings at ($0.08) EPS.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyadic International currently has a consensus rating of “Hold” and an average price target of $3.00.

Dyadic International Stock Performance

Dyadic International stock opened at $0.74 on Friday. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a market capitalization of $26.97 million, a P/E ratio of -3.22 and a beta of 1.18. The stock’s 50 day moving average is $0.81 and its 200 day moving average is $0.87. Dyadic International has a twelve month low of $0.65 and a twelve month high of $1.35.

Institutional Trading of Dyadic International

Several institutional investors have recently added to or reduced their stakes in DYAI. Bank of America Corp DE boosted its stake in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in Dyadic International by 627.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 300,200 shares during the last quarter. Truist Financial Corp boosted its stake in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Dyadic International during the 3rd quarter valued at $190,000. Finally, Marathon Capital Management purchased a new stake in Dyadic International during the 3rd quarter valued at $41,000. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.